| __timestamp | Blueprint Medicines Corporation | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 15746000 |
| Thursday, January 1, 2015 | 14456000 | 13392000 |
| Friday, January 1, 2016 | 19218000 | 9290000 |
| Sunday, January 1, 2017 | 27986000 | 7672000 |
| Monday, January 1, 2018 | 47928000 | 15293000 |
| Tuesday, January 1, 2019 | 96388000 | 22648000 |
| Wednesday, January 1, 2020 | 157743000 | 21864000 |
| Friday, January 1, 2021 | 195293000 | 37318000 |
| Saturday, January 1, 2022 | 237374000 | 48130000 |
| Sunday, January 1, 2023 | 295141000 | 108146000 |
| Monday, January 1, 2024 | 359272000 |
Unlocking the unknown
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Blueprint Medicines Corporation and Madrigal Pharmaceuticals, Inc. have taken different paths in this regard over the past decade. From 2014 to 2023, Blueprint Medicines saw a staggering increase in SG&A expenses, growing by approximately 3,600%, while Madrigal Pharmaceuticals experienced a more modest rise of around 590%. This stark contrast highlights Blueprint's aggressive expansion strategy, reflected in its 2023 SG&A expenses, which are nearly three times higher than Madrigal's. However, Madrigal's more conservative approach may suggest a focus on lean operations. As the biotech industry continues to evolve, these companies' strategies offer valuable insights into balancing growth with cost efficiency.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?